Altravax is a privately held biopharmaceutical company with corporate operations and research and development activities located in Sunnyvale, California. The Company is focused on the discovery and development of novel products to fight infectious diseases and other conditions. Our proprietary Immunogen Optimization System™ (IOS) offers unique opportunities to create novel vaccines or improve currently available alternatives to fill unmet medical needs. The Company has a robust pipeline of candidates at various stages of development, including a therapeutic vaccine against chronic hepatitis B infection and a preventive vaccine against all four dengue virus. Altravax seeks strategic alliances to develop these lead candidates for clinical testing.
Altravax’s mission is to improve human health, individually and globally, by preventing and treating diseases. We will motivate and empower our employees to focus on innovative ways to accelerate the development of biological products that are safe and efficacious.
Altravax scientists developed a high-throughput method for evaluating many vaccine candidates in animals through collaboration with Aldevron LLC (Fargo, ND). This ParallelaVax™ technology integrates the diversity-creating technology of MolecularBreeding™ directed molecular evolution with Aldevron’s Genetic Immunization and Antibody (GIA™) service. Additional improvements in documentation and infrastructure form the basis for the high-throughput capability of vaccine screening in animals.
ParallelaVax™ technology allows rapid vaccine screening through animals and is critical for the identification of vaccines with improved properties. It is comprised of the infrastructure, protocols, data tracking, and analytical methods wrapped in a quality system that allows for high-throughput animal testing. The quality system greatly facilitates the documentation required for interaction with the FDA prior to clinical testing. The ParallelaVax™ approach typically yields multiple lead candidates that can be further optimized or pursued in other types of studies. This is a necessary preliminary step before the resource-intensive evaluation of vaccine candidates in humans.
Altravax, Inc. has not received any reviews.
Altravax, Inc. has not received any endorsements.